GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » E10

Innate Pharma (XPAR:IPH) E10 : €-0.42 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Innate Pharma's adjusted earnings per share data for the fiscal year that ended in Dec. 2023 was €-0.090. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.42 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was -15.90% per year. During the past 5 years, the average E10 Growth Rate was -13.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Innate Pharma was 6.90% per year. The lowest was -22.10% per year. And the median was 3.50% per year.

As of today (2024-06-06), Innate Pharma's current stock price is € 2.555. Innate Pharma's E10 for the fiscal year that ended in Dec. 2023 was €-0.42. Innate Pharma's Shiller PE Ratio of today is .


Innate Pharma E10 Historical Data

The historical data trend for Innate Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma E10 Chart

Innate Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.22 -0.27 -0.32 -0.40 -0.42

Innate Pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.32 - -0.40 - -0.42

Competitive Comparison of Innate Pharma's E10

For the Biotechnology subindustry, Innate Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innate Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Shiller PE Ratio falls into.



Innate Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Innate Pharma's adjusted earnings per share data for the fiscal year that ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.09/118.3900*118.3900
=-0.090

Current CPI (Dec. 2023) = 118.3900.

Innate Pharma Annual Data

per_share_eps CPI Adj_EPS
201412 -0.390 99.860 -0.462
201512 -0.130 100.040 -0.154
201612 0.230 100.650 0.271
201712 -0.890 101.850 -1.035
201812 0.050 103.470 0.057
201912 -0.310 104.980 -0.350
202012 -0.810 104.960 -0.914
202112 -0.660 107.850 -0.725
202212 -0.730 114.160 -0.757
202312 -0.090 118.390 -0.090

Add all the adjusted EPS together and divide 10 will get our e10.


Innate Pharma  (XPAR:IPH) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Innate Pharma E10 Related Terms

Thank you for viewing the detailed overview of Innate Pharma's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Innate Pharma (XPAR:IPH) Business Description

Traded in Other Exchanges
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (XPAR:IPH) Headlines

No Headlines